INDICATIONS

• Relieve pain, tenderness, swelling and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints)
• Rheumatoid arthritis (arthritis caused by swelling of the lining of the joints)
• Ankylosing spondylitis (arthritis that mainly affects the spine)

PHARMACOLOGY Pharmacotherapeutic group: Non-steroidal anti-inflammatory and antirheumatic drugs, NSAIDs, Coxibs. ATC code: M01AH01 MECHANISM OF ACTION
Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 TxB2] formation) was observed in this dose range in healthy volunteers. DOSAGE AND ADMINISTRATION: As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient's need for symptomatic relief and response to therapy should be reevaluated periodically, especially in patients with osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis, Acute pain conditions, Acute gouty arthritis & Postoperative dental surgery pain. CONTRAINDICATIONS:

• Hypersensitivity to the active substance or to any of the excipients.
• Known hypersensitivity to sulfonamides.
• Active peptic ulceration or gastrointestinal (GI) bleeding.
• Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.
• In pregnancy and in women of childbearing potential unless using an effective method of contraception.
• Celecoxib has been shown to cause malformations in the two animal species studied. The potential for human risk in pregnancy is unknown but cannot be excluded.
• Breast-feeding
• Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score 210).
• Patients with estimated creatinine clearance <30 ml/min.
• Inflammatory bowel disease.
• Congestive heart failure (NYHA II-IV).
• Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.